New Zealand proposal for paliperidone, risperidone and olanzapine depot injections funding

14 February 2014

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to fund paliperidone depot injection (Invega Sustenna) from May 1, 2014, in conjunction with a price decrease on risperidone depot injection (Risperdal Consta), both through a provisional agreement with Janssen-Cilag Pty, a local unit of US health care giant Johnson & Johnson (NYSE: JNJ).

Both treatments would be subject to community and hospital restrictions for patients with schizophrenia and related psychoses. Amendments to the community and hospital restrictions for risperidone depot injection and olanzapine depot injection (Zyprexa Relprevv, from Eli Lilly; NYSE: LLY) are also proposed, which would allow patients with an approvals for risperidone depot and olanzapine depot to access paliperidone depot without having to re-meet the initial approval criteria (and vice versa).

Details of the proposal

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK